Solvonis Therapeutics (LSE:SVNS) Debt-to-EBITDA : (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Solvonis Therapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Solvonis Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was £0.00 Mil. Solvonis Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was £0.00 Mil. Solvonis Therapeutics's annualized EBITDA for the quarter that ended in Dec. 2025 was £-8.24 Mil. Solvonis Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2025 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Solvonis Therapeutics's Debt-to-EBITDA or its related term are showing as below:

LSE:SVNS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.95   Med: -0.21   Max: -0.01
Current: -0.01

During the past 8 years, the highest Debt-to-EBITDA Ratio of Solvonis Therapeutics was -0.01. The lowest was -1.95. And the median was -0.21.

LSE:SVNS's Debt-to-EBITDA is ranked worse than
100% of 304 companies
in the Biotechnology industry
Industry Median: 1.215 vs LSE:SVNS: -0.01

Solvonis Therapeutics  (LSE:SVNS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Solvonis Therapeutics Debt-to-EBITDA Related Terms

Solvonis Therapeutics Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Solvonis Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solvonis Therapeutics Debt-to-EBITDA Chart

Solvonis Therapeutics Annual Data
Trend May18 May19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial - - - - -

Solvonis Therapeutics Semi-Annual Data
Jun20 Dec20 Jun21 Jun22 Dec22 Jun23 Dec23 Jun24 Jun25 Dec25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

LSE:SVNS vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Solvonis Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Solvonis Therapeutics Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Solvonis Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Solvonis Therapeutics's Debt-to-EBITDA falls into.


Solvonis Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Solvonis Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -5.74
=0.00

Solvonis Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -8.238
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.

Solvonis Therapeutics Business Description

Other Exchanges J4I:Germany
Address Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry. The products in company's pipeline include SVN-001, SVN-002, SVN-015. SVN-114, and others.